1.646.889.1200|info@lifescipublicrelations.com

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

//With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of damaged or harmful proteins.

By | 2019-06-19T12:39:21-04:00 June 19th, 2019|News|Comments Off on With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.